Analyzing cytokine-induced growth arrest

doi:10.1038/protex.2013.020

Method Article

Analyzing cytokine-induced growth arrest

https://doi.org/10.1038/protex.2013.020

This work is licensed under a CC BY-NC 3.0 License

This protocol has been posted on Protocol Exchange, an open repository of community-contributed protocols sponsored by Nature Portfolio. These protocols are posted directly on the Protocol Exchange by authors and are made freely available to the scientific community for use and comment.

Version 1

posted 11 Feb, 2013

You are reading this latest protocol version

Here, we present the details of the experimental procedure used to analyze cytokine-induced growth arrest of different cancer cells in vitro.

Cell biology

Biological techniques

growth arrest

senescence markers

cytokines

The most stringent criterion defining cellular senescence is stable and permanent growth arrest in the absence of the inducing agent. Thus, we developed a method to first treat the cells with defined combinations of cytokines, then remove the cytokines and further cultivate the cells in the absence of cytokines.

Human cancer cell lines from the NCI 60 panel.

Human IFN-gamma (R&D Systems, Wiesbaden, Germany).

Human TNF (R&D Systems).

Trypan Blue Stain 0.4% from Gibco (Life Technologies; Darmstadt, Germany).

MultiscreenTM HTS 96 well Filtration Plates (Millipore, Billerica, MA, USA).

BrdU-based Cell Proliferation ELISA (Roche Diagnostics, Mannheim, Germany).

Vector®SG Substrate Kit for Peroxidase from Vector Laboratories (Burlingame, CA, USA).

Zeiss Axiovert 25 microscope (Zeiss, Oberkochen, Germany).

Neubauer counting-chamber (Karl Hecht GmbH, Sondheim, Germany).

ELISPOT reader (Bioreader®-3000; BIO-SYS, Karben, Germany).

Seed the different cancer cells at a density of 10 000 cells/cm2.
Incubate the cells overnight at 37°C; 5% CO2 to ensure adherence.
Treat the cells with either control medium or the cytokines mentioned above (standard concentration 100 ng/ml IFN-gamma plus 10 ng/ml TNF) for 4 - 5 d.
After treatment, remove the medium and trypsinize the cells.
Count viable cells (use trypan blue exclusion) under a Zeiss Axiovert 25 microscope using a Neubauer counting-chamber.
Reseed the cells at 20000 cells/cm2 in the absence of cytokines.
Grow the cells in complete RPMI 1640 medium until the control cultures reach confluence.
Repeat steps 4 - 6.
After passage 1 - 2 (p1 - p2), seed 1000 - 3000 viable cells on MultiscreenTM HTS 96 well Filtration Plates.
Incubate the cells overnight at 37°C; 5% CO2 to ensure adherence.
Measure proliferation by the BrdU-based Cell Proliferation ELISA in combination with the Vector®SG Substrate Kit for Peroxidase to visualize BrdU-incorporating cell clusters.
Count BrdU-positive spots with an ELISPOT reader.

The overall procedure takes about 2 - 3 weeks.

Ensure that at the beginning of cytokine treatment, the cells are 5 - 25% confluent.

The duration of the treatment depends on the growth kinetics of the cancer cells (incubate for approx. two duplication times).

The cytokine sensitivity of the different cancer cell lines may differ over a broad concentration range.

Toxic side effects of the cytokines have to be evaluated beforehand.

A cell line that is driven into senescence should show complete growth arrest after removal of the cytokines, i.e. there should not be any increase of the cell number of the cytokine-treated cells.

Braumüller, H. et al. T-helper-1-cell cytokines drive cancer into senescence. Nature, Epub ahead of print (2013). doi:10.1038/nature11824.

We declare that there may be a potential financial interest as far as cancer treatment by cytokine-induced senescence is concerned.

PDF

Version 1

posted 11 Feb, 2013

You are reading this latest protocol version

Analyzing cytokine-induced growth arrest

Status:

Version 1

Abstract

Introduction

Reagents

Equipment

Procedure

Timing

Troubleshooting

Anticipated Results

References

Competing Interests

Associated Publications

Status:

Version 1

Privacy Policy

Terms of Service